GenSight Biologics SA, a clinical-stage biotechnology company, operates within the Health Care sector, focusing on the discovery, development, and commercialization of therapies targeting mitochondrial and neurodegenerative diseases affecting the eye and central nervous system. Listed on the NYSE Euronext Paris, the company trades in euros (EUR).
As of February 5, 2026, GenSight Biologics’ share price closed at €0.083. Over the past year, the stock has experienced fluctuations, reaching a 52-week high of €0.316 on February 11, 2025, and a low of €0.0752 on February 2, 2026. This range indicates a relatively narrow trading band, suggesting a stable, low-volatility profile for the company’s shares.
The company’s market capitalization stands at €18,298,428, reflecting its modest valuation in the market. The price-to-earnings ratio is currently at -0.642, which is indicative of the company’s current financial performance and market perception.
In terms of corporate activity, GenSight Biologics reported no new public updates following the announcement of its extraordinary general meeting on January 29, 2026. The corporate actions disclosed during this meeting did not significantly impact the share price trajectory, which has remained within its 52-week range. This stability suggests a low-price, low-volume profile with steady performance and no recent catalysts to drive significant price changes.
Overall, GenSight Biologics presents a profile characterized by limited market interest, as evidenced by its modest valuation and stable share price. The company’s focus remains on advancing its therapeutic developments in the biotechnology sector, particularly in addressing complex neurodegenerative and mitochondrial diseases.
